Quick Takeaways
- Redmile Group, LLC filed SCHEDULE 13D/A for Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA).
- Disclosed ownership: 9.9%.
- Date of event: 12 May 2026.
Quoteable Key Fact
"Redmile Group, LLC disclosed 9.9% ownership in Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA) on 12 May 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | 950,994 | 0 | 950,994 | /s/ Jeremy C. Green | Managing Member | 0001425738 |
| Jeremy C. Green | 9.9% | 950,994 | 0 | 950,994 | /s/ Jeremy C. Green | Jeremy C. Green | 0001650527 |
| Redmile Biopharma Investments II, L.P. | 6.9% | 651,924 | 0 | 651,924 | /s/ Jeremy C. Green | Managing Member of Redmile Biopharma Investments II (GP), LLC, general partner of Redmile Biopharma Investments II, L.P. | 0001772230 |
| Redmile Strategic Long Only Trading Sub, Ltd. | 6.1% | 576,148 | 0 | 576,148 | /s/ Jeremy C. Green | Managing Member of Redmile Group, LLC, investment manager of Redmile Strategic Long Only Trading Sub, Ltd. | 0002048243 |